

PRACTITIONER

SAMPLE, DOCTOR

2602 S 24th Street
Phoenix, Arizona 85034

PATIENT

Name: SAMPLE, PATIENT

DOB: 01/01/1990

Gender: M

TEST	RESULT			REFERENCE (ELISA Index)
Alzheimer's LINX™ - Alzheimer's-Associated Immune Reactivity**	IN RANGE (Normal)	EQUIVOCAL*	OUT OF RANGE	
Brain Proteins				
Tau Protein	0.57			0.0-1.2
Amyloid-Beta Peptide		1.36		0.1-1.4
Rabaptin-5 + Presenilin			1.94	0.0-1.4
Alpha-Synuclein			>4.30	0.3-1.3
Growth Factors				
Beta Nerve Growth Factor			2.34	0.3-1.5
Brain Derived Neurotrophic Factor		1.90		0.1-1.2
Neurotrophins	0.60			0.3-1.6
Somatotropin			1.41	0.3-1.4
Enteric Nerve, Enzymes and Neurological Peptides				
Enteric Nerve + Vasoactive Intestinal Peptide	0.37			0.0-1.0
Transglutaminases			1.98	0.4-1.5
Pathogens				
Oral Pathogens	0.60			0.2-1.6
Enterococcus faecalis	0.96			0.5-1.6
Escherichia coli CDT + Salmonella CDT	0.44			0.2-1.3
Campylobacter jejuni CDT	0.31			0.1-1.5
Herpes Type-1	0.30			0.0-1.5
Chemicals				
Aluminums	<0.20			0.0-1.3
Dinitrophenyl	0.47			0.3-1.4
Ethyl + Methyl Mercury	0.33			0.2-1.1
Phthalates			2.65	0.2-1.2

** For details on the method of cooking, please see specification sheets. All analytes are tested for IgG .

* Reference ranges are calculated based on the mean \pm 2 standard deviations (SD). Results > 1 SD, and <2 SDs above the mean are considered to be equivocal. An equivocal result represents the range between negative and suspicious low positive results. Results >2 SDs are considered out of range, and positive.

Mark G. Kartub, M.D., Medical Director

Cyrex Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Test result data on its own does not constitute a diagnosis. Only a physician or qualified healthcare professional should interpret the significance of a clinical lab test or make a diagnosis. This test was developed and its performance characteristics determined by Cyrex Laboratories, LLC. The names and titles of tests and arrays are for reference purposes only.

PRACTITIONER

SAMPLE, DOCTOR

2602 S 24th Street
Phoenix, Arizona 85034

PATIENT

Name: SAMPLE, PATIENT

DOB: 01/01/1990

Gender: M

Foods Cross-Reactive to Amyloid Beta				
Egg Yolk, Raw + Cooked			1.91	0.0-1.4
Lentil Lectin + Pea Lectin	0.82			0.2-1.6
Tuna, Canned			1.44	0.1-1.3
Hazelnut Vicilin + Cashew Vicilin	0.60			0.2-1.4
Scallops + Squid		1.45		0.2-1.6
Caseins	<0.20			0.0-1.5
Alpha-Gliadin + Gliadin Toxic Peptide	1.09			0.2-1.4
Non-Gluten Proteins	1.29			0.3-1.6
Blood-Brain Barrier Proteins				
Blood-Brain Barrier Protein + Claudin-5	0.91			0.2-1.4
Aquaporins	0.57			0.0-1.3
Neurofilament Proteins			2.45	0.1-1.2

** For details on the method of cooking, please see specification sheets. All analytes are tested for IgG .

* Reference ranges are calculated based on the mean \pm 2 standard deviations (SD). Results > 1 SD, and <2 SDs above the mean are considered to be equivocal. An equivocal result represents the range between negative and suspicious low positive results. Results >2 SDs are considered out of range, and positive.

Mark G. Kartub, M.D., Medical Director

Cyrex Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Test result data on its own does not constitute a diagnosis. Only a physician or qualified healthcare professional should interpret the significance of a clinical lab test or make a diagnosis. This test was developed and its performance characteristics determined by Cyrex Laboratories, LLC. The names and titles of tests and arrays are for reference purposes only.